Advertisement · 728 × 90
#
Hashtag
#duchennesmusculardystrophy
Advertisement · 728 × 90
BeardedDadBod Gaming
BeardedDadBod Gaming
@beardeddadbod82.bsky.social
1 year ago
Post image

This weekend—February 21st, 22nd, and 23rd—I’m going live for a charity stream, and we’re raising money for myDMDHero, supporting those battling Duchenne’s Muscular Dystrophy #DuchennesMuscularDystrophy #TwitchStreamer #KickStreamer #SmallStreamer #BeardedGamer #CharityStream #myDMDHero

2 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
Will Elevidys Receive Approval from the European Medicines Agency (EMA)? Patients with Duchenne muscular dystrophy (DMD) around Europe are anxiously awaiting the EMA's approval of Sarepta's application for its gene treatment Elevidys. Will Elevidys Receive Approval from the European Medicines Agency (EMA)? 📌 In Which Countries Is Elevidys Approved? 📌 In Which Countries Has Roche Applied for Authorization for Elevidys? 📌 Interim Results from Elevidys’ Embark Clinical Trial Could Impact Decision 📌 Why Are Sarepta and Roche Only Applying for Registration in Certain Countries? 📌 Families Concern if Sarepta for a Different Gene Therapy Will Not Be Approved by EMA 📌 Genethon and Sarepta Collaborated in 2017 📌 Pricing Policies Should Be Revised

Will Elevidys Receive Approval from the European Medicines Agency (EMA)? Patients with Duchenne muscular dystrophy (DMD) around Europe are anxiously awaiting the EMA's approval of Sarepta's application for its gene treatment Elevidys. Will Elevidys Receive Approval from the European Medicines Agency (EMA)? 📌 In Which Countries Is Elevidys Approved? 📌 In Which Countries Has Roche Applied for Authorization for Elevidys? 📌 Interim Results from Elevidys’ Embark Clinical Trial Could Impact Decision 📌 Why Are Sarepta and Roche Only Applying for Registration in Certain Countries? 📌 Families Concern if Sarepta for a Different Gene Therapy Will Not Be Approved by EMA 📌 Genethon and Sarepta Collaborated in 2017 📌 Pricing Policies Should Be Revised

Will Elevidys Receive Approval from the European Medicines Agency (EMA)?

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneheroes #musculardystrophy #gene #dna #roche @roche #elevidys #sarepta

0 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
Roche Announces New Results from the EMBARK Study of Elevidys in Outpatients with Duchenne Muscular Dystrophy (DMD) Today, Roche revealed encouraging topline data from the second year of the EMBARK trial, a worldwide, double-blind, randomised phase III investigation of Elevidys (delandistrogene moxeparvovec), the first gene therapy to be authorized for the treatment of Duchenne muscular dystrophy. When compared to a predetermined propensity-weighted untreated external control group, statistically significant and clinically meaningful improvements were seen in three important motor function tests two years following Elevidys treatment: NSAA, TTR, and 10MWR. Between one and two years following dose, the functional differences between those receiving Elevidys and those in the external control group grew. When taken as a whole, these findings show that Elevidys has consistently benefited.

Roche Announces New Results from the EMBARK Study of Elevidys in Outpatients with Duchenne Muscular Dystrophy (DMD) Today, Roche revealed encouraging topline data from the second year of the EMBARK trial, a worldwide, double-blind, randomised phase III investigation of Elevidys (delandistrogene moxeparvovec), the first gene therapy to be authorized for the treatment of Duchenne muscular dystrophy. When compared to a predetermined propensity-weighted untreated external control group, statistically significant and clinically meaningful improvements were seen in three important motor function tests two years following Elevidys treatment: NSAA, TTR, and 10MWR. Between one and two years following dose, the functional differences between those receiving Elevidys and those in the external control group grew. When taken as a whole, these findings show that Elevidys has consistently benefited.

Roche Announces New Results from the EMBARK Study of Elevidys in Outpatients with Duchenne Muscular Dystrophy (DMD)

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #gene #dna #brazil #roche @roche #elevidys #sarepta

1 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
dmd warrior dmdwarrior

dmd warrior dmdwarrior

WE WILL FIGHT DUCHENNE and WE WILL WIN 💪

👉 dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna

0 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
FDA Grants Rare Pediatric Disease Designation to Nippon Shinyaku’s Exon 51 Skipping Study (NS-051/NCNP-04) Nippon Shinyaku declared that NS-051/NCNP-04, a medication being developed to treat Duchenne Muscular Dystrophy (DMD), has been granted Rare Pediatric Disease Designation by the Food and Drug Administration (FDA). Nippon Shinyaku and the National Center of Neurology and Psychiatry jointly discovered the antisense oligonucleotide NS-051/NCNP-04. By omitting a portion of the dystrophin gene’s genetic material, NS-051/NCNP-04 creates a functioning dystrophin protein with a little shorter chain length, which should prevent the decline in muscle function.

FDA Grants Rare Pediatric Disease Designation to Nippon Shinyaku’s Exon 51 Skipping Study (NS-051/NCNP-04) Nippon Shinyaku declared that NS-051/NCNP-04, a medication being developed to treat Duchenne Muscular Dystrophy (DMD), has been granted Rare Pediatric Disease Designation by the Food and Drug Administration (FDA). Nippon Shinyaku and the National Center of Neurology and Psychiatry jointly discovered the antisense oligonucleotide NS-051/NCNP-04. By omitting a portion of the dystrophin gene’s genetic material, NS-051/NCNP-04 creates a functioning dystrophin protein with a little shorter chain length, which should prevent the decline in muscle function.

FDA Grants Rare Pediatric Disease Designation to Nippon Shinyaku’s Exon 51 Skipping Study (NS-051/NCNP-04)

👉 Learn More: dmdwarrior.com

#dmd #duchenne #bmd #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #exon51 #exon51skipping #nipponshinyaku #exonskipping

1 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
What is Bobcat mRNA? How Does Bobcat mRNA Work for Duchenne Muscular Dystrophy? What is Bobcat mRNA? Bobcat mRNA is a proprietary linear mRNA technology that produces high-quality mRNA encoding large proteins (greater than 13 kb) in a highly efficient and cost-effective manner. A lipid nanoparticle (LNP) delivers it. Elixirgen Therapeutics is first looking into how Bobcat mRNA can be used with dystrophin, which is the largest human gene known.

What is Bobcat mRNA? How Does Bobcat mRNA Work for Duchenne Muscular Dystrophy? What is Bobcat mRNA? Bobcat mRNA is a proprietary linear mRNA technology that produces high-quality mRNA encoding large proteins (greater than 13 kb) in a highly efficient and cost-effective manner. A lipid nanoparticle (LNP) delivers it. Elixirgen Therapeutics is first looking into how Bobcat mRNA can be used with dystrophin, which is the largest human gene known.

What is Bobcat mRNA? How Does Bobcat mRNA Work for Duchenne Muscular Dystrophy?

👉 Learn More: dmdwarrior.com

#dmd #duchenne #bmd #becker
#genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneheroes #musculardystrophy #gene #dna #bobcat #mrna #bobcatmrna

0 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
Insmed’s Gene Therapy (INS1201) Poised to Challenge Duchenne Muscular Dystrophy (DMD) For its INS1201 Duchenne (DMD) gene therapy, Insmed intends to initiate Phase I clinical trials in the first part of the year 2025. Insmed is getting ready to use its ground-breaking gene therapy, INS1201, to combat Duchenne muscular dystrophy. Insmed intends to start Phase I clinical trials for INS1201 in the first half of 2025 after the FDA approved its investigational new drug (IND) application in December 2024. What is Insmed INS1201 Gene Therapy? Learn More: dmdwarrior.com

Insmed’s Gene Therapy (INS1201) Poised to Challenge Duchenne Muscular Dystrophy (DMD) For its INS1201 Duchenne (DMD) gene therapy, Insmed intends to initiate Phase I clinical trials in the first part of the year 2025. Insmed is getting ready to use its ground-breaking gene therapy, INS1201, to combat Duchenne muscular dystrophy. Insmed intends to start Phase I clinical trials for INS1201 in the first half of 2025 after the FDA approved its investigational new drug (IND) application in December 2024. What is Insmed INS1201 Gene Therapy? Learn More: dmdwarrior.com

Insmed’s Gene Therapy (INS1201) Poised to Challenge Duchenne Muscular Dystrophy (DMD)

👉 Learn More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneheroes #musculardystrophy #gene #dna #insmed #ins1201

0 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
Solid Biosciences Releases Information on Clinical Trial for SGT-003 Gene Therapy Solid Biosciences shared detailed information about the clinical trials of its SGT-003 Gene Therapy developed for the treatment of Duchenne Muscular Dystrophy. Solid Biosciences shared that four patients have been dosed in the SGT-003 gene therapy clinical trial; it was well tolerated in all patients with no side effects observed; and data from the first three patients could be available in Q1 2025.

Solid Biosciences Releases Information on Clinical Trial for SGT-003 Gene Therapy Solid Biosciences shared detailed information about the clinical trials of its SGT-003 Gene Therapy developed for the treatment of Duchenne Muscular Dystrophy. Solid Biosciences shared that four patients have been dosed in the SGT-003 gene therapy clinical trial; it was well tolerated in all patients with no side effects observed; and data from the first three patients could be available in Q1 2025.

Solid Biosciences Releases Information on Clinical Trial for SGT-003 Gene Therapy

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneawareness #gene #dna #solidbiosciences #sgt003

0 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera AGAMREE (vamorolone) has been recommended for use in the National Health Service (NHS) in England, Wales, and Northern Ireland for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 and up by the National Institute for Health and Care Excellence (NICE), according to Santhera Pharmaceuticals.

NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera AGAMREE (vamorolone) has been recommended for use in the National Health Service (NHS) in England, Wales, and Northern Ireland for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 and up by the National Institute for Health and Care Excellence (NICE), according to Santhera Pharmaceuticals.

NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera

👉 Read More: dmdwarrior.com

#dmd #duchenne #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #agamree #vamorolone #santhera #NICE #uk #england #wales #northernireland

0 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
ImmunoForge Receives FDA IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy The U.S. Food and Drug Administration (FDA) has approved ImmunoForge's Phase 2 clinical trial IND for "Pemziviptadil (development code name PF1804)," a treatment for DMD (Duchenne Muscular Dystrophy) cardiomyopathy. A medication for DMD cardiomyopathy, pemziviptadil is used once a week and is based on ImmunForge’s ELP Platform (Elastin Like Polypeptide Platform), a long-acting pharmacological platform. In order to improve cardiac function, pemziviptadil, a vasoactive intestinal peptide (VIP), preferentially works on the vasoactive intestinal peptide receptor 2 (VPAC2) to promote heart contraction and relaxation.

ImmunoForge Receives FDA IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy The U.S. Food and Drug Administration (FDA) has approved ImmunoForge's Phase 2 clinical trial IND for "Pemziviptadil (development code name PF1804)," a treatment for DMD (Duchenne Muscular Dystrophy) cardiomyopathy. A medication for DMD cardiomyopathy, pemziviptadil is used once a week and is based on ImmunForge’s ELP Platform (Elastin Like Polypeptide Platform), a long-acting pharmacological platform. In order to improve cardiac function, pemziviptadil, a vasoactive intestinal peptide (VIP), preferentially works on the vasoactive intestinal peptide receptor 2 (VPAC2) to promote heart contraction and relaxation.

ImmunoForge Receives FDA IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #musculardystrophy #gene #dna #ImmunoForge #Pemziviptadil #pf1804

0 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
Vamorolone (Agamree) Approved in Scotland The Scottish Medicines Consortium (SMC) approved the Agamree (Vamorolone) for use by NHS Scotland. The medication vamorolone, also marketed under the brand name Agamree, has been approved by the Scottish Medicines Consortium (SMC) as a therapy option for Duchenne muscular dystrophy in patients four years of age and older in Scotland as of today, Monday, January 13 2025.

Vamorolone (Agamree) Approved in Scotland The Scottish Medicines Consortium (SMC) approved the Agamree (Vamorolone) for use by NHS Scotland. The medication vamorolone, also marketed under the brand name Agamree, has been approved by the Scottish Medicines Consortium (SMC) as a therapy option for Duchenne muscular dystrophy in patients four years of age and older in Scotland as of today, Monday, January 13 2025.

Vamorolone (Agamree) Approved in Scotland

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna #agamree #vamorolone #santhera #scotland #uk #england

1 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
Plans for DYNE-101 in DM1 and DYNE-251 in DMD Are Announced by Dyne Therapeutics Dyne Therapeutics announces clinical trial plans for DYNE-101 and DYNE-251, targeting myotonic dystrophy and Duchenne muscular dystrophy. Dyne Therapeutics announced positive clinical data for its therapies DYNE-101 and DYNE-251 during an investor event on January 10, 2025. DYNE-101 for myotonic dystrophy type 1 (DM1) demonstrated significant splicing correction and functional improvements, leading Dyne to plan a global Registrational Expansion Cohort of the ACHIEVE trial with a registrational dose of 6.8 mg/kg Q8W and a potential U.S. Accelerated Approval submission in H1 2026. Meanwhile, DYNE-251, targeting Duchenne muscular dystrophy (DMD), is also pursuing U.S. Accelerated Approval based on dystrophin as a surrogate endpoint, with data expected by late 2025 to support an early 2026 submission. Both programs show promise in transforming treatment paradigms for these genetic diseases.

Plans for DYNE-101 in DM1 and DYNE-251 in DMD Are Announced by Dyne Therapeutics Dyne Therapeutics announces clinical trial plans for DYNE-101 and DYNE-251, targeting myotonic dystrophy and Duchenne muscular dystrophy. Dyne Therapeutics announced positive clinical data for its therapies DYNE-101 and DYNE-251 during an investor event on January 10, 2025. DYNE-101 for myotonic dystrophy type 1 (DM1) demonstrated significant splicing correction and functional improvements, leading Dyne to plan a global Registrational Expansion Cohort of the ACHIEVE trial with a registrational dose of 6.8 mg/kg Q8W and a potential U.S. Accelerated Approval submission in H1 2026. Meanwhile, DYNE-251, targeting Duchenne muscular dystrophy (DMD), is also pursuing U.S. Accelerated Approval based on dystrophin as a surrogate endpoint, with data expected by late 2025 to support an early 2026 submission. Both programs show promise in transforming treatment paradigms for these genetic diseases.

Plans for DYNE-101 in DM1 and DYNE-251 in DMD Are Announced by Dyne Therapeutics

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneheroes #musculardystrophy #gene #dna #dyne #dyne251 #dyne101

2 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
Avidity Biosciences Prepares for Three Rare Muscle Disease Programs’ 2025 BLA Submission and Commercialization Avidity Biosciences, Inc., a biopharmaceutical company producing Antibody Oligonucleotide Conjugates (AOC) RNA therapies, announced its progress and goals for a transformative 2025. A biopharmaceutical firm dedicated to developing a novel class of RNA treatments known as Antibody Oligonucleotide Conjugates (AOCsTM), Avidity Biosciences, Inc., today reported its advancements and plans for a game-changing year in 2025. These significant expected milestones include completing three potentially registrational programs, submitting a Biologics License Application (BLA) for delpacibart zotadirsen (del-zota) for individuals with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44), getting ready for several product launches in DMD44, myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD), and establishing a completely integrated, international business to support an expanding AOC pipeline in precision cardiology and neuromuscular diseases.

Avidity Biosciences Prepares for Three Rare Muscle Disease Programs’ 2025 BLA Submission and Commercialization Avidity Biosciences, Inc., a biopharmaceutical company producing Antibody Oligonucleotide Conjugates (AOC) RNA therapies, announced its progress and goals for a transformative 2025. A biopharmaceutical firm dedicated to developing a novel class of RNA treatments known as Antibody Oligonucleotide Conjugates (AOCsTM), Avidity Biosciences, Inc., today reported its advancements and plans for a game-changing year in 2025. These significant expected milestones include completing three potentially registrational programs, submitting a Biologics License Application (BLA) for delpacibart zotadirsen (del-zota) for individuals with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44), getting ready for several product launches in DMD44, myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD), and establishing a completely integrated, international business to support an expanding AOC pipeline in precision cardiology and neuromuscular diseases.

Avidity Biosciences Prepares for Three Rare Muscle Disease Programs’ 2025 BLA Submission and Commercialization

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #duchenne #gene #dna #avidity #aviditybiosciences #raredisease

0 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
Percheron Disappointed in Avicursen (ATL1102) Study For Duchenne (DMD) Percheron plans to broaden pipeline following Avicursen (ATL1102) disappointment. After disappointing Phase IIb results for avicursen last month, Percheron will adopt a three-pronged business strategy. Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing Phase IIb results last month. In a letter to shareholders published today (6 January), the chair of the board Dr Charmaine Gittleson, alongside non-executive director Dr Gil Price and managing director Dr James Garner, told shareholders that the company “will undertake a broad strategic review of the company’s pipeline to more comprehensively evaluate alternative sources of value within the current assets”. The review follows negative topline results from the Phase IIb trial (NCT05938023) of avicursen in boys with non-ambulatory DMD. Announced on 18 December, the results demonstrated that the trial did not meet its primary endpoint, which was the Performance of the Upper Limb 2.0 (PUL2.0) score at week 25 compared to placebo.

Percheron Disappointed in Avicursen (ATL1102) Study For Duchenne (DMD) Percheron plans to broaden pipeline following Avicursen (ATL1102) disappointment. After disappointing Phase IIb results for avicursen last month, Percheron will adopt a three-pronged business strategy. Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing Phase IIb results last month. In a letter to shareholders published today (6 January), the chair of the board Dr Charmaine Gittleson, alongside non-executive director Dr Gil Price and managing director Dr James Garner, told shareholders that the company “will undertake a broad strategic review of the company’s pipeline to more comprehensively evaluate alternative sources of value within the current assets”. The review follows negative topline results from the Phase IIb trial (NCT05938023) of avicursen in boys with non-ambulatory DMD. Announced on 18 December, the results demonstrated that the trial did not meet its primary endpoint, which was the Performance of the Upper Limb 2.0 (PUL2.0) score at week 25 compared to placebo.

Percheron Disappointed in Avicursen (ATL1102) Study For Duchenne (DMD)

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #duchenne #musculardystrophy #percheron #avicursen #atl1102 #NCT05938023 #percherontherapeutics

0 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group "We look forward to working with Santhera to make AGAMREE available to patients globally on an unlicensed basis in those territories where it is not currently licensed or reimbursed. ” said Julie Gosper, Senior Vice President, Europe and Partner Markets at Clinigen. Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product is not otherwise commercially available. Santhera Pharmaceuticals and Clinigen Group announce that they have signed a Supply and Distribution Agreement for AGAMREE in countries where the product can currently not be commercially obtained via Santhera or one of its current distribution partners. The agreement will enable access to AGAMREE on a case-by-case basis for patients with Duchenne muscular dystrophy (DMD) in situations where the treating physician deems there to be no suitable alternatives and where regulations allow for it. This agreement allows Santhera to receive the majority share of revenue generated from the supply of product in these additional countries.

Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group "We look forward to working with Santhera to make AGAMREE available to patients globally on an unlicensed basis in those territories where it is not currently licensed or reimbursed. ” said Julie Gosper, Senior Vice President, Europe and Partner Markets at Clinigen. Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product is not otherwise commercially available. Santhera Pharmaceuticals and Clinigen Group announce that they have signed a Supply and Distribution Agreement for AGAMREE in countries where the product can currently not be commercially obtained via Santhera or one of its current distribution partners. The agreement will enable access to AGAMREE on a case-by-case basis for patients with Duchenne muscular dystrophy (DMD) in situations where the treating physician deems there to be no suitable alternatives and where regulations allow for it. This agreement allows Santhera to receive the majority share of revenue generated from the supply of product in these additional countries.

Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #agamree #vamorolone #santhera #Clinigen #clinigengroup

0 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
One day our children will be able to enjoy life freely. dmd warrior. dmdwarrior.

One day our children will be able to enjoy life freely. dmd warrior. dmdwarrior.

One day our children will be able to enjoy life freely.

Together, we are stronger. 💪

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #musculardystrophy #gene #dna #newyear #snowboarding #2025 #skiing #world #followme

0 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
dmdwarrior dmd warrior

dmdwarrior dmd warrior

WE WILL FIGHT DUCHENNE and WE WILL WIN 💪

👉 dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna

1 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
No one cares about your child as much as you do. Together, we are stronger. 💪 dmd warrior

No one cares about your child as much as you do. Together, we are stronger. 💪 dmd warrior

No one cares about your child as much as you do. Together, we are stronger. 💪

#dmd #duchenne #bmd #becker
#genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna

1 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
Muscular Dystrophy Association Announces Over $5 Million in Research Grants to Advance Neuromuscular Disease Research

Muscular Dystrophy Association Announces Over $5 Million in Research Grants to Advance Neuromuscular Disease Research

Muscular Dystrophy Association Announces Over $5 Million in Research Grants to Advance Neuromuscular Disease Research

#dmd #duchenne #bmd #becker
#genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #duchenneawareness #musculardystrophy #gene #dna #mda

1 0 1 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
Novartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy

Novartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy

Novartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy

Novartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy

Novartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy

Novartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy

Novartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy

Source: www.novartis.com/stories/addr...

#dmd #bmd #genetherapy #dmdwarrior #dmdwarriors
#duchennemusculardystrophyawareness #duchennewarriors #duchennesmusculardystrophy #duchenne #duchenneawareness #duchenneheroes #novartis

0 0 0 0